{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:37:17Z","timestamp":1771609037291,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brazilian Journal of Otorhinolaryngology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bjorl.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T19:43:06Z","timestamp":1617478986000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-2320","authenticated-orcid":false,"given":"Wilma T.","family":"Anselmo-Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-6292","authenticated-orcid":false,"given":"Edwin","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2218-8417","authenticated-orcid":false,"given":"Fabrizio R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-0496","authenticated-orcid":false,"given":"Marcel M.","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9073-868X","authenticated-orcid":false,"given":"Renato","family":"Roithmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-0541","authenticated-orcid":false,"given":"Eduardo M.","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-3688","authenticated-orcid":false,"given":"M\u00e1rcio","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-2337","authenticated-orcid":false,"given":"Marco A.","family":"Fornazieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-5074","authenticated-orcid":false,"given":"Thiago F.P.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9965-5052","authenticated-orcid":false,"suffix":"Jr.","given":"Jo\u00e3o F.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5003-0828","authenticated-orcid":false,"given":"Marcus M.","family":"Lessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-3387","authenticated-orcid":false,"given":"Richard L.","family":"Voegels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3384-3664","authenticated-orcid":false,"given":"Ot\u00e1vio B.","family":"Piltcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eulalia","family":"Sakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-5317","authenticated-orcid":false,"given":"Fabiana C.P.","family":"Valera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjorl.2021.03.003_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/0194599820965233","article-title":"Targeted Molecular Therapies in Allergy and Rhinology","volume":"164","author":"Damask","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type-2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0030","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0035","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2017.03.006","article-title":"Biologics and biomarkers for asthma, urticaria, and nasal polyposis","volume":"139","author":"Casale","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","article-title":"A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"123","author":"Codispoti","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00151829-200403030-00006","article-title":"Omalizumab \u2014 a review of its use in the management of allergic asthma","volume":"3","author":"Bang","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1945892418814768","article-title":"Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps","volume":"33","author":"Kartush","year":"2019","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0055","unstructured":"Xolair\u00ae (omalizumabe). VPS12 = Xolair_Bula_Profissional aprovada pela ANVISA em 11\/01\/2021. https:\/\/portal.novartis.com.br\/upload\/imgconteudos\/1815.pdf."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-017-0219-4","article-title":"Asthma biomarkers in the age of biologics","volume":"13","author":"Kim","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00405-019-05650-y","article-title":"Omalizumab versus intranasal steroids in the post\u2010operative management of patients with allergic fungal rhinosinusitis","volume":"277","author":"Mostafa","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE- mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0075","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0080","doi-asserted-by":"crossref","first-page":"110-6.e1","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/0003489417731782","article-title":"Anti-IgE and Anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis","volume":"126","author":"Rivero","year":"2017","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13643-015-0157-5","article-title":"Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review","volume":"4","author":"Hong","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0105","first-page":"473","article-title":"Effectiveness of omalizumab in the treatment of chronic rhinosinusitis with nasal polyps","volume":"3","author":"Santos","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0115","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.amjoto.2015.05.008","article-title":"Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma","volume":"36","author":"Gan","year":"2015","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0120","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","article-title":"Biotherapeutics in chronic rhinosinusitis with and without nasal polyps","volume":"5","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0135","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1034\/j.1398-9995.2003.00110.x","article-title":"Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis","volume":"58","author":"Gevaert","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0150","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.158.8.3902","article-title":"Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia","volume":"158","author":"Simon","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0155","unstructured":"Nucala (mepolizumab) for injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2015."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0160","unstructured":"Fda.gov [Internet]. Nucala (mepolizumab) Label FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf. Published 2017."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0165","unstructured":"Fda.gov [Internet]. Cinqair (reslizumab) Label FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. Published 2017."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0170","unstructured":"Fda.gov (Internet).Fasenra (benralizumab) https:\/\/www.astrazeneca.com\/media-centre\/pressreleases\/2017\/fasenra-benralizumab-receives-us-fdaapproval-for-severe-uncontrolled-eosinophilic-asthma14112017.html. Published 2017."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0175","unstructured":"Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (OSTRO) (https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03401229."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0180","unstructured":"Effect of Mepolizumab in Severe Bilateral Nasal Polyps https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03085797."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0185","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti\u2013IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0190","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0194599820939964","article-title":"Role of biologics in chronic rhinosinusitis with nasal polyposis: state of the art review","volume":"164","author":"Kim","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0200","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/0003489417731782","article-title":"Anti-IgE and Anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis","volume":"126","author":"Rivero","year":"2017","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0205","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0210","unstructured":"United States Food and Drug Administration. Dupixent Prescribing Information (approved March 28, 2017). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Published 2019. [Accessed 30 November 2020]."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0215","unstructured":"European Medicines Agency. Dupixent. Extension of indication variation assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/dupixent-h-c-4390-ii-0017-epar-assessment-report-variation_en.pdf. Published 2019. [Accessed 30 November 2020]."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18176\/jiaci.0254","article-title":"Dupilumab: A new paradigm for the treatment of allergic diseases","volume":"28","author":"Sastre","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0225","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0230","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0235","doi-asserted-by":"crossref","first-page":"2447-9.e2","DOI":"10.1016\/j.jaip.2019.03.023","article-title":"Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"7","author":"Bachert","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0240","doi-asserted-by":"crossref","first-page":"2462-5.e1","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0245","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health\u2010related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0250","article-title":"Biologics for chronic rhinosinusitis","volume":"2","author":"Chong","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0255","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0260","doi-asserted-by":"crossref","first-page":"2462-5.e1","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0265","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","author":"Mustafa","year":"2020","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.anai.2020.07.014","article-title":"Dupilumab use in recalcitrant allergic fungal rhinosinusitis","volume":"125","author":"Lo","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0275","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Consultas Anvisa Medicamentos Dupixent. https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/25351189487201920\/?substancia=26064. Published 2019."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0280","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0285","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight."},{"key":"10.1016\/j.bjorl.2021.03.003_bib0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0295","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cpdd.775","article-title":"A Phase 1, Randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men","volume":"9","author":"Sakamoto","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0300","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0305","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-020-01513-x","article-title":"CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma","volume":"21","author":"Emson","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-020-01503-z","article-title":"SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma","volume":"21","author":"Wechsler","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-020-01541-7","article-title":"DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0320","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0325","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0330","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a european collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0335","doi-asserted-by":"crossref","first-page":"1186-93.e1","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0340","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0350","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/key117","article-title":"Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0355","article-title":"Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical effectiveness, cost-effectiveness, and guidelines [Internet]","author":"Ho","year":"2017","journal-title":"Ottawa (ON): Can Agency Drugs Technol Health"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0360","article-title":"Anti-cytokine targeted therapies for ANCA-associated vasculitis","volume":"9","author":"Bala","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert Board Meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjorl.2021.03.003_bib0370","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/alr.21373","article-title":"Olfactory outcomes in chronic rhinosinusitis with nasal polyposis after medical treatments: a systematic review and meta-analysis","volume":"4","author":"Banglawala","year":"2014","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Brazilian Journal of Otorhinolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1808869421000628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1808869421000628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:37:37Z","timestamp":1761723457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1808869421000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1808869421000628"],"URL":"https:\/\/doi.org\/10.1016\/j.bjorl.2021.03.003","relation":{},"ISSN":["1808-8694"],"issn-type":[{"value":"1808-8694","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil","name":"articletitle","label":"Article Title"},{"value":"Brazilian Journal of Otorhinolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjorl.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Associa\u00e7\u00e3o Brasileira de Otorrinolaringologia e Cirurgia C\u00e9rvico-Facial. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}